本帖最后由 老马 于 2013-3-13 13:43 编辑
3 i3 A; ?, y+ _6 L5 w
; F3 s3 n! v8 s& n3 v4 x0 T健择(吉西他滨)+顺铂+阿瓦斯汀/ \7 l p, s V6 w5 G0 Y
Gemzar +Cisplatin + Avastin
, C2 B1 Z; d# t Z8 X" m# Phttp://annonc.oxfordjournals.org/content/21/9/1804.full
7 B6 m3 ^) Z/ k+ T5 M% J: aOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : A" z6 O- R# P/ Q `
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 Y4 I7 }" i4 }4 h+ @* q# c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 0 l: A' N/ V/ G6 [ B+ M
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 841)
8 `' z) [; ^6 C
华为网盘附件:) ^6 h3 b0 s/ r+ W7 w* q
【华为网盘】ava.JPG
, \5 B8 p* }0 Q2 A; E |